STING1

Overview

STING1 (Stimulator of Interferon Genes 1), encoded by the gene TMEM173 (also catalogued as Wikidata Q18055374), is a transmembrane adaptor protein that serves as a central hub in the innate immune sensing pathway. Located on the endoplasmic reticulum membrane, STING1 functions downstream of cyclic GMP-AMP synthase (cGAS), which detects cytosolic double-stranded DNA from damaged, infected, or malignant cells. Upon activation by cyclic dinucleotides (CDNs) — including the second messenger cGAMP produced by cGAS — STING1 undergoes conformational changes that recruit and activate TBK1 and IRF3, ultimately driving transcription of type I interferons and other pro-inflammatory cytokines. This signaling cascade, collectively known as the cGAS–STING pathway, bridges the detection of nucleic acid danger signals to a robust adaptive immune response, making the p53/cGAS/STING axis a critical checkpoint in tumor surveillance and antiviral defense.

Because STING1 occupies a nodal position in innate immunity, it has attracted intense interest as a therapeutic target in oncology and inflammatory disease. Pharmacological agonists of STING1 can reprogram the immunosuppressive tumor microenvironment by recruiting and activating dendritic cells and other immune effectors, thereby potentiating cancer immunotherapy. Conversely, in conditions of chronic sterile inflammation — such as pulmonary fibrosis — pathological STING1 activity in macrophages drives tissue damage, making its targeted silencing equally therapeutically relevant.

Focus of Latest Publications

Recent literature reflects a dual focus on STING1 as both an activatable immune stimulus in cancer settings and a suppressible driver of inflammatory pathology.

cancer immunotherapy and agonist development have dominated the field. A 2026 comprehensive review in Bioorganic Chemistry (PMID 41785706) catalogued the evolution of benzimidazole-derived non-cyclic dinucleotide STING agonists, emphasizing structure–activity relationships and the therapeutic potential of small-molecule STING1 activation for cancer immunotherapy. This class of agonists bypasses the pharmacokinetic limitations of natural CDNs, which — as highlighted in a Journal of Controlled Release study (PMID 41702512) — require frequent intratumoral administration in both preclinical head and neck squamous cell carcinoma models and clinical trials. That study addressed delivery constraints by embedding a CDN within a multidomain peptide hydrogel-liposome composite, enabling controlled release in oral cancer models. A companion study (PMID 41702511) demonstrated that co-delivery of a STING agonist alongside blockade of Indoleamine 2,3-dioxygenase 1 (IDO1) robustly activates type I conventional dendritic cells (cDC1s); crucially, depletion of STING in host Tmem173−/− mice or deficiency in Batf3-dependent cDC1s abolished therapeutic efficacy, confirming that intact STING1 signaling in the host immune compartment is indispensable.

Combination modalities exploiting the cGAS–STING pathway have expanded rapidly. Radiotherapy was shown to be a potent activator of this axis: a Small (2026) study (PMID 42023514) engineered scintillating nanoparticles capable of X-ray-responsive Mn²⁺ release, driving cGAS–STING activation to enhance radio-immunotherapy. Similarly, a Biomaterials (2026) report (PMID 41512497) achieved multimodal tumor immunotherapy through a Mn(III)-tuned sonozyme system (SCYS-P@MnCO) that combined sonodynamic enhancement, glutathione depletion, hypoxia alleviation, and STING activation, yielding efficacy against both local and distant tumors. The TMEM protein family context was formalized in an International Immunopharmacology (2026) review (PMID 41864016), which recognized TMEM173 (STING1) as the defining example of immune-activating TMEM proteins within the tumor immune microenvironment.

Resistance to Targeted therapies has also been linked to STING1. A Chemical Biology & Drug Design (2026) study (PMID 42059424) reported that cepharanthine, a natural bisbenzylisoquinoline alkaloid, reverses gefitinib resistance in non-small cell lung cancer by simultaneously suppressing the AKT/P70S6K survival axis and activating the STING-mediated innate immune pathway, with experiments performed in the NCI-H1975 gefitinib-resistant cell line.

Real-time monitoring of STING1 activity emerged as a methodological priority. A study in Analytical Chemistry (2026) (PMID 41980121) developed photoactivatable cascade DNAzyme nanomachines for amplified imaging of tumor responses to STING-activated immunotherapy, arguing that real-time monitoring of enzymatic cascades following STING activation is essential for elucidating immunotherapy mechanisms. CD47 blockade — an immune checkpoint that suppresses the "don't-eat-me" signal — was integrated with STING pathway activation in a metal-organic framework (MOF) nanodrug for melanoma immunotherapy (Colloids and Surfaces B, 2026; PMID 41723989), highlighting the complementarity of innate immune activation via STING1 and adaptive checkpoint inhibitor strategies.

Epigenetic and expression profiling added a clinical layer. A Scientific Reports (2026) study (PMID 41942521) identified significant hypomethylation of the STING1 promoter in renal cell carcinoma tumor tissues relative to normal tissues, which strongly correlated with increased STING1 mRNA expression across three RCC cohorts, linking DNA methylation status to prognostic and immune significance.

Pathological STING1 activity was addressed in a Molecular Therapy (2026) study (PMID 41795185), which targeted macrophage-specific STING1 in the context of pulmonary fibrosis. Rather than activating the pathway, the authors sought to attenuate it using inhalable lipid nanoparticles engineered for selective macrophage uptake via surface phosphatidylserine, carrying a CRISPR-Cas9 mRNA payload to edit the STING1 locus and ameliorate fibrotic disease.

Key Publications

• Jun Inhalable lipid nanoparticles for macrophage-specific STING gene editing to ameliorate pulmonary fibrosis. (Molecular therapy : the journal of the American Society of Gene Therapy, 2026, PMID 41795185): "This system leverages surface phosphatidylserine for selective uptake and encapsulates a CRISPR-Cas9 mRNA payload."
• May Cepharanthine Reverses Gefitinib Resistance in NSCLC by Concurrently Inhibiting AKT/P70S6K Survival Signaling and Activating STING-Mediated Immune Response. (Chemical biology & drug design, 2026, PMID 42059424): "Here, we report that cepharanthine (CEP), a natural bisbenzylisoquinoline alkaloid, effectively reverses gefitinib resistance through concurrent suppression of the AKT/P70S6K survival axis and activation of the Stimulator of Interferon Genes (STING)-mediated innate immune pathway."
• Apr Photoactivatable Cascade DNAzyme Nanomachines for Amplified Imaging of Tumor Response to STING-Activated Immunotherapy. (Analytical chemistry, 2026, PMID 41980121): "Real-time monitoring of enzymatic cascades following Stimulator of Interferon Genes (STING) activation is vital for elucidating the mechanisms and efficacy of cancer immunotherapies."
• Apr X-Ray-Responsive Mn2+ Release via Scintillating Nanoparticles Drives cGAS-STING Activation for Enhanced Radio-Immunotherapy. (Small (Weinheim an der Bergstrasse, Germany), 2026, PMID 42023514): "Radiotherapy (RT) represents a potent approach to activate the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway."
• Apr Co-delivery of a STING agonist and indoleamine 2,3-dioxygenase 1 blockade activates type I dendritic cells in cancer. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41702511): "Depletion of STING in the host (Tmem173-/- mice) or deficiency in type I conventional DCs (cDC1s, Batf3-/- mice) abolishes therapeutic efficacy."
• Apr A multidomain peptide hydrogel-liposome composite for controlled release of a cyclic dinucleotide in oral cancer. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41702512): "Cyclic dinucleotides (CDNs) are STING agonists that hold promise in combination approaches, but they require frequent intratumoral administration when used in both preclinical models of HNSCC and clinical trials."
• Apr Prognostic significance and immune correlation of STING expression and promoter methylation in renal cell carcinoma. (Scientific reports, 2026, PMID 41942521): "Our findings revealed significant hypomethylation of the STING promoter in RCC tumor tissues compared with normal tissues, which strongly correlated with increased STING mRNA expression across all three RCC cohorts."
• Apr Roles and clinical translational prospects of TMEM proteins in the tumor immune microenvironment. (International immunopharmacology, 2026, PMID 41864016): "Notably, TMEM173 (STING) and TMEM176B exemplify the immune-activating and context-dependent regulatory functions of this family, underscoring its therapeutic potential."
• Apr Atomic-valence engineering of a Mn(III)-tuned sonozyme system for multimodal tumor immunotherapy. (Biomaterials, 2026, PMID 41512497): "Enhanced sonodynamic immunotherapy efficacy against both local and distant tumors was achieved by the synergism of VO-mediated sonodynamic enhancement, Mn (III)-mediated GSH depletion, hypoxia alleviation and STING activation."
• Apr "Self" signal-suppressed metal-organic framework (MOF) nanodrug for enhanced immunotherapy of melanoma via CD47 blockade. (Colloids and surfaces. B, Biointerfaces, 2026, PMID 41723989): "In addition to immune checkpoint blockade, the STING-related pathway has emerged as a critical mechanism in activating innate immunity against tumors."